ADmit Therapeutics
Carla Trapero has a diverse work experience in various organizations. Carla is currently working as a Project Manager at ADmit Therapeutics since July 2021. Previously, they held the position of a Professora associada en Histologia at Universitat de Barcelona from October 2019 to October 2021. Carla also worked as a Technician at Bellvitge Biomedical Research Institute - IDIBELL in June 2021 and as a Research Technician at Institut de Recerca Biomèdica de Lleida Fundació Dr. Pifarré - IRBLLEIDA in May 2021. Prior to that, they served as a Predoctoral researcher at Bellvitge Biomedical Research Institute - IDIBELL from September 2017 to March 2021.
Carla Trapero has an extensive education history in the field of biomedical sciences. Carla completed their Bachelor's degree in Biomedical Sciences at Universitat de Barcelona from 2012 to 2016. Following their undergraduate studies, Carla pursued a Master's degree in Clinical Analysis Laboratory at Universitat Pompeu Fabra, which they completed between 2016 and 2017.
Carla went on to further expand their knowledge and expertise by pursuing a Doctor of Philosophy (PhD) in Biomedicine at Universitat de Barcelona. Carla engaged in doctoral research from 2017 to 2021, focusing on an advanced level of study in the field of biomedicine.
In addition to their academic pursuits, Carla also sought to enhance their skills in project management by pursuing a Master's degree in Project Management at OBS Business School. Carla joined this program in 2022 and is expected to complete it in 2023.
Furthermore, Carla acquired a "Título Experto en Inmunología e Inmunoterapia en cáncer" from Universidad Francisco de Vitoria during the period of 2020 to 2021. Although the field of study for this degree is not specified, it indicates their interest and specialized knowledge in immunology and immunotherapy related to cancer treatment.
Overall, Carla Trapero has accumulated a diverse educational background, encompassing bachelor's, master's, and doctoral degrees, along with specialized expertise in various areas of biomedical sciences, clinical analysis, and project management.
This person is not in the org chart
This person is not in any teams
ADmit Therapeutics
ADmit Therapeutics is a biotechnology company that specializes in the development of early Alzheimer's disease diagnosis tests. The company's test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA by next-generation sequencing, enabling medical practitioners with aneasy way to detect early-stage Alzheimer.